National NuvaRing Lawyers Warn of Study Linking NuvaRing to Higher Risk of Dangerous Blood Clots, Pulmonary Embolism and Deep Vein Thrombosis

Share Article

According to British Medical Journal Study, Users of NuvaRing have a 6.5 Times Increased Risk of Dangerous Blood Clots, Including Pulmonary Embolism and Deep Vein Thrombosis (DVT), Compared to Women who do not use Hormonal Contraceptives. Compared to Users of Combined Oral Contraceptives containing Levonorgestrel, the Increased Blood Clot Risk with Vaginal Rings like NuvaRing was 90% Higher

PW Logo
. To reduce the number of serious blood clots associated with riskier methods of birth control, such as NuvaRing, the study authors advised that more women choose birth control pills.

Parker Waichman LLP, a national law firm dedicated to protecting the legal rights of people injured by defective medical devices, is warning today that women who use hormonal vaginal rings, like NuvaRing, for birth control may face a significantly higher risk of suffering serious blood clots, including pulmonary embolism and deep vein thrombosis (DVT), compared to those who do not use a hormonal contraceptive, as well as women who use certain birth control pills. According to a study published online in the British Medical Journal on May 10, users of vaginal rings like NuvaRing have a 6.5 times increased risk of confirmed venous thrombosis compared with non-users of hormonal contraception. The article also noted that "the vaginal ring conferred a 90% higher risk of venous thrombosis than did combined oral contraceptives containing levonorgestrel."    [bmj.com/content/344/bmj.e2990]

The British Medical Journal study drew data from national registries in Denmark to follow all Danish women aged 15-49 who were not pregnant and had no history of previous thrombotic disease or cancer. The study compared the rate of venous thrombosis in women using no hormonal birth control to rates in women using one of several kinds of non-oral hormonal contraceptives, including the vaginal ring.

According to Parker Waichman LLP, Venous Thrombosis is a class of serious blood clots that includes deep vein thrombosis and pulmonary embolism. Such blood clots can cause heart attacks, strokes and sudden death. To reduce the number of serious blood clots associated with riskier methods of birth control, such as NuvaRing, the study authors advised that more women choose birth control pills.

According to Parker Waichman LLP, NuvaRing is a flexible ring that is inserted into the vagina, and provides month-long birth control by emitting a continuous, low dose of ethinyl estradiol, and a progestin called etonogestrel for 21 days. NuvaRing has been named in hundreds of lawsuits currently pending in a federal multidistrict litigation before Rodney W. Sippel of the U.S. District Court, Eastern District of Missouri (MDL No. 1964). Plaintiffs involved in this litigation allege that NuvaRing users face an increased danger of suffering blood clots, deep vein thrombosis, pulmonary embolism, heart attacks, strokes and sudden death. Plaintiffs further allege that Merck & Co. and Organon, the makers of NuvaRing, failed to adequately warn patients and their doctors about the potential for NuvaRing blood clots and other side effects.

Parker Waichman LLP continues to offer free legal consultations to victims of NuvaRing side effects. If you or a loved suffered a blood clot, including deep vein thrombosis or pulmonary embolism, or any other side effect that could be associated with the use of NuvaRing, please contact their office by visiting the firm’s NuvaRing side effects page at http://www.yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

For more information regarding NuvaRing side effect lawsuits and Parker Waichman LLP, please visit: http://www.yourlawyer.com or call 1-800-LAW-INFO (1-800-529-4636).

Contact:

Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Gary Falkowitz, Managing Attorney
Parker Waichman LLP
(800) 529-4636
Email >
Visit website